Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

Ehsan Shabbir, MD, Sarah L Mott, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5376.

https://doi.org/10.1182/blood.V130.Suppl_1.5376.5376

Published: 2017

Journal Articles

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Anthony R. Mato, MD, William G Wierda, MD PhD, Matthew S. Davids, MD, Bruce D. Cheson, MD, Steven Coutre, MD, Michael Choi, MD, Richard R. Furman, Leonard Heffner, MD, Paul M. Barr, MD, Herbert Eradat, Lang Zhou, Maria Verdugo, MD, Jalaja Potluri, Jeffrey Jones, MD

Blood (2017) 130 (Supplement 1): 834.

https://doi.org/10.1182/blood.V130.Suppl_1.834.834

Published: 2017

Journal Articles

Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study

Mohamed Samour, MBBS, Caner Saygin, MD, Rashid Abdallah, RN, Suman Kundu, MS, MBA, Keith R. McCrae, MD

Blood (2016) 128 (22): 210.

https://doi.org/10.1182/blood.V128.22.210.210

Published: 2016

Journal Articles

Oxygen Sensing By Succinate Dehydrogenase Regulates Transcriptional Response to Hypoxia in Monocytes

Bora E. Baysal, MD PhD, Shraddha Sharma, PhD, Robert T Taggart, PhD, Santosh Patnaik, MD PhD

Blood (2015) 126 (23): 998.

https://doi.org/10.1182/blood.V126.23.998.998

Published: 2015

Journal Articles

Patient Outcomes with Proteosome Inhibitor Bortezomib in Multiple Myeloma at an English District General Hospital

Anil Vaikunth Kamat, MD FRCP, FRCPath, MBA (Health Executive), Tariq Shafi, FRCP, FRCPath, Raphael A. Ezekwesili, FRCPath

Blood (2014) 124 (21): 5745.

https://doi.org/10.1182/blood.V124.21.5745.5745

Published: 2014

Journal Articles

Three Novel EPAS1/HIF2A Somatic and Germline mutations Associated with Polycythemia and Pheochromocytoma/Paraganglioma.

Felipe R Lorenzo V, M.D., PhD., Zhengping Zhuang, Chunzhang Yang, Mark Ng Tang Fui, Hariprasad Vankayalapati, Karel Pacak, Josef T. Prchal, MD

Blood (2012) 120 (21): 2080.

https://doi.org/10.1182/blood.V120.21.2080.2080

Published: 2012

Journal Articles

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),

Aline Clavert, MD, Peric Zina, MD, Xavier Cahu, MD, Patrice Chevallier, MD, Eolia Brissot, Florent Malard, Thierry Guillaume, Jacques Delaunay, MD, Sameh Ayari, Viviane Dubruille, Beatrice Mahe, Nicolas Blin, MD, Thomas Gastinne, Virginie Roland, Steven Le Gouill, MD, PhD, Jean-Luc Harousseau, Philippe Moreau, MD, Noel Milpied, MD, Mohamad Mohty

Blood (2011) 118 (21): 4100.

https://doi.org/10.1182/blood.V118.21.4100.4100

Published: 2011

Journal Articles

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Kenneth C. Anderson, MD, Kelvin Lee, MD, Dawn DePaolo, Kena C. Miller, NP, Sybil Zildjian, Robert J. Fram, MD, Qin

Blood (2007) 110 (11): 1174.

https://doi.org/10.1182/blood.V110.11.1174.1174

Published: 2007

Journal Articles

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher Alban Chanan-Khan, MD, Sundar Jagannath, MD, Robert L. Schlossman, MD, Robert J. Fram, MD, Richard M. Falzone, Mary F. Ruberti, Samantha K. Welch, Dawn DePaolo, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 3574.

https://doi.org/10.1182/blood.V108.11.3574.3574

Published: 2006

Journal Articles

Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia

P Kogner, A Ericsson, G Barbany, H Persson, E Theodorsson, O Bjork

Blood (1992) 80 (5): 1324–1329.

https://doi.org/10.1182/blood.V80.5.1324.1324

Published: 1992

NARROW

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Pomalidomide in Hereditary Hemorrhagic Telangiectasia: Interim Results of a Phase I Study

Oxygen Sensing By Succinate Dehydrogenase Regulates Transcriptional Response to Hypoxia in Monocytes

Patient Outcomes with Proteosome Inhibitor Bortezomib in Multiple Myeloma at an English District General Hospital

Three Novel EPAS1/HIF2A Somatic and Germline mutations Associated with Polycythemia and Pheochromocytoma/Paraganglioma.

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Phase I Study of BB-10901 (huN901-DM1) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Neuropeptide Y (NPY) synthesis in lymphoblasts and increased plasma NPY in pediatric B-cell precursor leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only